Laryngeal squamous cell carcinoma (LSCC) is the most common type of head and neck squamous cell carcinoma (HNSCC). LSCC accounts for 1–2% of all malignancies diagnosed worldwide (Vokes et al, 1993; ...
The CD44v6 protein was discovered in the 1990s by KIT. It acts as a co-receptor for so-called receptor tyrosine kinases, such as MET or VEGFR-2, that depend on CD44 for their activation. These enzymes ...
Researchers from Karolinska Institutet and collaborators have reported on the characterization of novel human anti-CD44v6 antibodies aimed to be used as anticancer agents in the radiotherapy of CD44v6 ...
Phase II Trial of Docetaxel, Cisplatin, Fluorouracil, and Leucovorin as Induction for Squamous Cell Carcinoma of the Head and Neck PURPOSE: Thyroid cancer is the most frequently occurring endocrine ...
Cells in a pancreatic tumor, with yellow areas showing where C-MET and CD44v6 are together--Courtesy of KIT Working with the knowledge that the CD44v6 protein acts as a co-receptor for receptor ...
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces the launch of PRE-CISE, a Eurostars-funded research collaboration with Danish PreTT and TetraKit ...
Dual-nuclide biodistribution and therapeutic potential of CD44v6 antibody-based radiotherapy for ATC
Anaplastic thyroid cancer (ATC) is a rare but aggressive form of thyroid cancer, accounting for nearly 50% of thyroid cancer-related deaths. Given its poor prognosis, the identification of new ...
Peptides might help fighting pancreatic tumors/biologists studied the CD44v6 isoform and discovered peptides that inhibit metastatic spreading Due to their rapid metastatic spread, pancreatic tumors ...
This news release is available in German. Due to their rapid metastatic spread, pancreatic tumors are among the most aggressive types of cancer. Only three to five percent of patients have a survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results